Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

7.315 +0.065 (+0.90%)
Streaming Delayed Price Updated: 1:51 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire
News headline image
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.